To explore whether FOXA2 had a role in ferroptosis to mediate chemosensitivity and resistance in CRC, OXA, recommended as a first‐line therapeutic drug for clinical metastatic CRC, was subjected to HCT‐116 and SW480 cells with or without FOXA2 absence. This evidence concerns the gene FOXA2 and colorectal carcinoma.